



Journal Website:  
<https://theusajournals.com/index.php/ijmscr>

Copyright: Original content from this work may be used under the terms of the creative commons attributes 4.0 licence.

## OPTIMIZATION OF COMPLEX TREATMENT OF PURULENT-NECROTIC WOUNDS ON THE FOOT IN DIABETES MELLITUS

Submission Date: Sep 19, 2024, Accepted Date: Sep 24, 2024,

Published Date: Sep 29, 2024

Crossref doi: <https://doi.org/10.37547/ijmscr/Volume04Issue09-07>

**Zokhirov Adkhamjon Rafiqovich**

Assistant Of General Surgery No.2, Tashkent Medical Academy, Tashkent City, Uzbekistan

**Abdulkarimov Sarvar Azizbek Ogli**

3rd Year Student Of Faculty Of Medicine, Tashkent Medical Academy, Tashkent City, Uzbekistan

**Khakimova Dilyora Ulugbekovna**

4th Year Student Of Faculty Of General Medicine Kimyo International University In Tashkent, Tashkent City, Uzbekistan

**Solijonova Umidaxon Ilhomjonovna**

3rd Year Student Of Faculty Of General Medicine Kimyo International University In Tashkent, Tashkent City, Uzbekistan

**Sherkulov Bobur Bahodir Ogli**

3rd Year Student Of Faculty Of General Medicine Kimyo International University In Tashkent, Tashkent City, Uzbekistan

**Fayzullayeva Dilnoza Baxtiyor Qizi**

2nd Year Student Of Faculty Of General Medicine Kimyo International University In Tashkent, Tashkent City, Uzbekistan

### ABSTRACT

In patients with purulent-necrotic processes in diabetes mellitus, the condition of the IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, TNF- $\alpha$ , INF system based on the dynamics of cytokine levels was studied. Complex surgical treatment of the drug Reomannisol corrects the balance of cytokines, allowing them to have an antioxidant effect on the cytokine system.

## KEYWORDS

diabetic foot syndrome, cytokine system, complex treatment, Rheomannisol.

## INTRODUCTION

Diabetes mellitus (DM) is a chronic autoimmune disease. When purulent-necrotic lesions of diabetic heel syndrome appear, an inflammatory reaction appears and manifests itself in the form of a local reaction, which can lead to a systemic response. As a result of bacterial action, under the influence of humoral factors, activation occurs in the main phagocytosis cells – neutrophils (polymorphonuclear leukocytes), monocytes (macrophages) and platelets. Activated cells begin to produce inflammatory mediators (cytokines) into the blood, which are involved in the regulation of vascular tone, hemostasis, and cell proliferation. Atherosclerosis of blood vessels in patients with diabetes occurs 8-10 years earlier than in the general population. Therefore, an inflammatory reaction occurs against the background of changes in metabolism and circulatory disorders. The pathogenetic mechanism of diabetes is complex, but the latest research data suggests that the participation of cytokines plays a large role in this disease. Cytokines are conditionally anti-inflammatory: natural immune regulators involved in inflammatory formation (IL-1, IL-2, IL-6, IL-12, TNF- $\alpha$ ) and anti-inflammatory by pancreatic  $\beta$ -cells that depressant to insulin production: special immune regulators of

inflammatory response (IL-4, IL-10, IL-13, INF- $\gamma$ ) these cytokines have protective and antidiabetic effects. In addition, there are cytokines that regulate specific immune reactions (IL-2 and IL-4, transformative growth factor (TGF- $\beta$  va et al.). It is involved in protein activation, differentiation and growth of mature lymphocytes. A number of cytokines (IL-1, IL-6, TNF- $\alpha$ , erythropoietin) can also have effects such as distension, which is simple hormones. In addition, a similar single cell can secrete several different cytokines and the same cytokines at the same time, or different cells can produce several different or identical cytokines. Therefore, the importance of cytokines in the formation of diabetes mellitus, on the one hand, and in the formation of an inflammatory reaction, on the other, is interesting to obtain information about the state of the cytokine in patients with DFS. The state of the cytokine system at the time of the development of purulent-necrotic processes in patients with DFS is completely unclear. Given the lack of research, DFS is solved by the dynamic state of the cytokine system in patients with purulent-necrotic processes and recurrence of purulent-necrotic processes. It was decided to study the dynamics of cytokine levels in the blood serum of anti -



inflammatory cytokines-interleukins IL-1 $\beta$ , IL-2, IL-6, IL-8, tumor necrosis factor-TNF- $\alpha$ , as well as gamma-interferon (IFN- $\gamma$ ) and anti-inflammatory interleukins IL-4, IL-10 patients. In our opinion, perhaps the imbalance of cytokines will help predict the course of the purulent-necrotic process and determine the tactics of surgical treatment. In addition, the state of the cytokine balance is of interest in patients with recurrence of purulent-necrotic complications of DFS. Cytokine management balance is currently seen as a

new direction of immunotherapeutic effects in the treatment of patients with purulent-necrotic lesions of DFS.

The purpose of the work. By studying the dynamics of anti-inflammatory cytokine levels: analysis of the need and possibility of immunocorrection by studying cytokine status in IL-1 $\beta$ , IL-2, IL-4, IL-6, IL-8, IL-10, TNF- $\alpha$ , INF- $\gamma$  patients on the development and recurrence of purulent-necrotic processes of DFS.

**Table 1. In normal patients, the amount of cytokines and the number of cells in the peripheral blood serum**

Cytokines	Concentration of cytokines in blood plasma, pg/ml	Production of cells in blood culture, pg/ml	
		Spontaneous	Induced
IL-1 $\beta$	0-50	0-50	1000-5000
IL-2	0	0	2-10 ED/ml
IL-4	0-50	30-50	100-400
IL-6	0-50	30-50	1000-3000
IL-8	0-50	30-100	1000-5000
IL-10	0-50	30-50	1000-3000
TNF- $\alpha$	0-50	30-50	500-3000
INF- $\gamma$	0-10	10-100	1000-5000

**Table 2. Characteristics of operations in group I**

Type of operation	Frequency of operations (n=60)	
	abs.	%
<b>Amputations at the hip level</b>	20	33,3
<b>Amputations at the lower leg level</b>	6	10
<b>Amputations at the foot level</b>	12	20
<b>Amputations at the level of the fingers</b>	11	18,3
<b>Amputations at the level of the fingers</b>	7	11,7
<b>Necrectomy</b>	4	6,7

**MATERIALS AND METHODS**

The concentration of cytokines in the blood plasma was determined using the StatFax 2100 immunological complex (manufactured by Cytokin LLC, St. Petersburg) by enzyme immunoassay (IFA). The obtained results are carried out using descriptive and non-parametric statistical methods on a personal computer with mathematical processing using Statistica 6.0 software (Table 1). Control parameters of the manufacturer's cytokine norms were used - the

normative parameters obtained as a result of testing the donors were obtained from the manufacturer Cytokin LLC, St. Petersburg, Russian Federation. Plasma collection and cytokine level testing were performed on day 1 before surgery and on days 3, 5, 7, and 10 after surgery. The study was conducted in three phases and, accordingly, the patients were divided into 3 research groups: Group I (control group) - blood serum of patients with purulent-necrotic lesions of diabetes for the study of the cytokine system; II group (comparison group) - blood serum obtained during the

treatment of patients with purulent-necrotic lesions of diabetes with ozone therapy and peosorbilact - 200.0 ml (YURIYA-FARM LLC, Ukraine); Group III (main group) - blood sera obtained during the treatment of patients with purulent-necrotic lesions of diabetes with ozone therapy and reomannisol - 200.0 ml (REKA-MED FARM LLC, Uzbekistan).

The first stage: to determine the imbalance of cytokines, it consists in taking the blood plasma of 60 patients with purulent-necrotic lesions of diabetes and determining the amount of cytokines in it. 60 patients were treated at various levels in the Yiringli surgical department of the Yakkasaroy District Medical Association between 2021 and 2023. The age range of the patients was between 48-60 years. Neuropathic form of DFS - 25 people (type 1 DM - 2 patients, type 2 DM - 23): 12 were men and 13 women, and neuroischemic form of DFS - 35 patients (all with type 2 DM): 15 men and consisted of 20 women. The characteristics of operations performed in this group of patients are presented in Table 2. Most often, amputations were performed at the thigh level - 33.3%, heel area - 20%, finger level - 18.3%, necrotomy - 6.7%, sequestrectomy - 11.7%. Upper amputations were also performed as the main option, as a result of the failure of the approach to save vital organs: at the thigh level - in 33.3% of cases, at the heel level - in 20%.

Results and discussions in the first group. The dynamics of the level of cytokines in the first group is presented

in Table 3. In the analysis of the indicators of the level of cytokines, the picture of growth was revealed: inflammatory cytokines: IL-1 $\beta$ , IL-2, IL-6, IL-8, TNF- $\alpha$  and anti-inflammatory cytokines: IL-4, IL-10, IFN- $\gamma$ .

IL-1 $\beta$ : ranged from 7.25 $\pm$ 0.24 to 2.9 $\pm$ 0.1 pg/ml, but all changes were within the acceptable range. IL-1b appears in the blood plasma when a pathogenic agent enters the body for the first time or in autoimmune type 1 DM. Perhaps, with the first purulent-septic injury of DFS, the biological activity of this cytokine does not increase, that is, due to the insufficient activity of macrophages, monocytes, lymphocytes due to the endothelial reaction, as well as the functional activity of fibroblasts decreases.

IL-2: ranges from 6.97 $\pm$ 0.13 to 1.09 $\pm$ 0.48 pg/ml, which is 3-2 times higher than normal values, especially in lymphocytes responsible for the immune system is explained by activation. In the postoperative period, the cytokine level decreases, but it is higher than the norm during discharge from the hospital, which allows us to consider this decrease as a residual reaction of the immune system, which can be associated with positive clinical dynamics.

IL-6: ranged from 90.1 $\pm$ 0.76 to 12.59 $\pm$ 1.9 pg/ml. A high level of cytokines on the first day, a decrease to normal by the 7th day, an acute phase with a decrease after the clinical relief of the inflammatory process, as well

as an indirect reaction of the endothelial system in the purulent-necrotic focus indicate high protein activity.

IL-8: ranged from 129±0.13 to 579±0.11 pg/ml by day 7 and decreased to 51.8±0.11 pg/ml at hospital discharge,

suggesting that indicates the presence of an acute purulent-necrotic process and the possibility of chronicity, since cytokine levels remain at higher levels during clinical recovery.

Table 3. Level of cytokines (in pg/ml) in patients of the first group

Cytokines/ Days	Day 1	Day 3	Day 5	Day 7	Day 10	Discharge (11-12 days)
IL-1β	7,25±0,24 *	5,67±0,1 3*	4,56±0,1 *	4,14±0,14 *	2,9 ±0,1*	6,2±0,7*
IL-2	6,22±0,3 *	6,97±0,1 3*	6,1±0,2 *	6,5±0,1 5*	5,1±0,11*	1,09±0,48*
IL-4	235±0,13 *	255±0,5 *	280±0,1 2*	199±0,1 6*	101±0,1*	45±0,2*
IL-6	90,1±0,7 6*	80,5±0,6 6*	60±0,12 *	16,02±0,23 *	13±0,5*	12,59±1,9*
IL-8	129±0,13 *	199,3±0,11 11*	245,5±0,1 1*	579±0,11 11*	65,7±0,1 5*	50,8±0,11*
IL-10	59,08±0,7 2*	58,12±0,3 3*	50±0,4 *	51,68±0,73 *	36±0,15 *	6,65±1,33*
TFN-α	51,51±0,7 *	55±0,1*	56±0,14 *	51,01±0,94 *	40±0,16 *	2,2±0,52*
INF-γ	68,3±0,1 *	105,1±0,14 14*	101±0,11 *	45,8±0,13 13*	40±0,11 *	10,4±0,14*

Note: \* - p < 0,05.



TNF- $\alpha$ : ranged to  $56 \pm 0.14$  pg/ml by day 5 and decreased to  $2.2 \pm 0.52$  pg/ml at hospital discharge. It shows the immunomodulatory and anti-inflammatory effects of the cytokine caused by the activation of macrophages, neutrophils, eosinophils and endothelial cells, as well as the metabolic disorders associated with hyperglycemia.

IL-4: increased to  $280 \pm 0.12$  pg/ml by day 5 and fluctuated between  $235 \pm 0.13$  pg/ml, and decreased to  $45 \pm 0.2$  pg/ml at hospital discharge. Such dynamics can be explained by the growth and activity of macrophages, lymphocytes, and, accordingly, a high level of anti-inflammatory cytokines. IL-4 performs regulatory functions.

IL-10: ranged from  $59.08 \pm 0.72$  to  $6.65 \pm 1.33$  pg/ml. It is an antagonist of anti-inflammatory cytokines and performs a regulatory function, reduces its level, shows a favorable direction of this process with clinical improvement.

IFN- $\gamma$ : fluctuated from  $105.1 \pm 0.14$  pg/ml to  $10.4 \pm 0.14$  pg/ml with a decrease on day 3. This dynamic can be explained by clinical recovery. IFN- $\gamma$  has a wide spectrum of immunomodulatory activity, regulates and protects it, establishes a balance of activity with fibroblasts and macrophages and monocytes. In addition, on the first day, high levels of inflammatory and anti-inflammatory cytokines are observed, their number increases slightly, and on the fifth day, it

decreases with a clinically favorable level. A high level of IL-8 indicates activation in response to acute inflammation and the possibility of the process becoming chronic. This stage of the research made it possible to study the state of the cytokine system in purulent-necrotic lesions of DFS.

The second stage: studying the dynamics of cytokines in recurrent purulent-necrotic lesions of diabetes.

Materials and methods of the second stage - comparison group. The second group of the study included 40 patients (men and women aged 45 to 74). In 2021-2023, patients with DFS with recurrent purulent-necrotic lesions of diabetes were taken in the Department of Purulent Surgery of the Yakkasaroy District Medical Association. With the neuropathic form of DFS - 15 people: 5 men and 10 women and the neuroischemic form of DFS - 25 patients: 9 men and 16 women. The characteristics of operations performed in this group of patients are presented in Table 4. All patients, regardless of the severity of the disease, were treated locally with ozonized physiological solution, and 200.0 ml of Reosorbilact was administered intravenously once, the course of treatment was 7 days.

Determination of ozone concentration. To prepare an ozonated physiological solution, we ozonate 200.0 ml of physiological solution for 10 minutes at a concentration of 3-4 mg/l at a concentration of 3-4 mg/l

and for 10 minutes in the apparatus "Medozons Beauty" (MEDOZONS LLC, Russia), then its dose is determined by the following formula:

$$D=C \times V \times t;$$

D – ozone concentration dose;

C – ozone concentration, mg/l;

V - oxygen exit rate, l/min;

t – time, min;

The purulent area of each patient is washed 3 times a day with ozonized physiological solution for 15-20 minutes. The number of operations is greater than the number of patients. This is explained by the fact that various operations were performed in one patient to preserve the quality of life and ability to work: necrotomy - 20%, amputation at the level of fingers - 22.9%, amputations at the level of the foot - 2.9%.

Table 4. Characteristics of operations in group II

Type of operation	Frequency of operations (n=40)	
	abs.	%
Amputations at the hip level	23	65,7
Amputations at the lower leg level	0	0
Amputations at the foot level	2	5,0
Amputations at the level of the fingers	8	22,9
Amputations at the level of the fingers	5	14,3
Necrectomy	7	20



However, high amputations were performed when the tactics of saving vital organs were ineffective or when there was no prospect of saving the leg at the time of the initial examination - 65.7%.

Results and discussions in the second group. The dynamics of the state of the cytokine system in the blood plasma of patients in this group of patients is presented in Table 5. It should be noted that 1 day before the operation, only an increase in the level of IL-8 up to 182.7 pg/ml is detected. It increased to 245.5

pg/ml by day 5 and decreased to 60.9 pg/ml on days 11-12. The activity and level of IL-8 is considered to be related to the activity of IL-1 $\beta$ , IL-4, and TNF- $\alpha$ , as well as the effects of endotoxins of gram-negative bacterial microorganisms. In addition, IL-8-producing cells are monocytes, macrophages, T-lymphocytes, neutrophils, fibroblasts, keratinocytes, hepatocytes, endothelial cells, epithelial cells, chondrocytes. IL-8 as a mediator stimulates chemotaxis of subpopulations of neutrophils, T-lymphocytes and basophils; lysosomal enzymes activate neutrophils.

Table 5. Level of cytokines (in pg/ml) in patients of the second group

Cytokines/ Days	Day 1	Day 3	Day 5	Day 7	Day 10	Discharge (11-12 days)
IL-1 $\beta$	10,2 $\pm$ 0,2*	13 $\pm$ 1,19*	7 $\pm$ 1,12*	3,4 $\pm$ 0,14*	5 $\pm$ 1,1*	2,2 $\pm$ 0,4*
IL-2	0	0	0	0	0	0
IL-4	32 $\pm$ 1,14*	30 $\pm$ 1,12*	31 $\pm$ 1,11*	25 $\pm$ 1,13*	17 $\pm$ 1,4*	9 $\pm$ 1,1*
IL-6	18,1 $\pm$ 0,7*	15 $\pm$ 1,2*	23 $\pm$ 1,1*	15,02 $\pm$ 1,3*	14,9 $\pm$ 1,9*	10,59 $\pm$ 1,9*
IL-8	182,7 $\pm$ 1,1*	201,5 $\pm$ 1,1*	245,5 $\pm$ 1,3*	210,1 $\pm$ 1,2*	103,7 $\pm$ 1,4*	70,9 $\pm$ 1,9*
IL-10	9,08 $\pm$ 0,7*	23,1 $\pm$ 0,9*	19,3 $\pm$ 0,8*	10,68 $\pm$ 1,3*	14,5 $\pm$ 1,1*	15,65 $\pm$ 1,2*
TFN- $\alpha$	21,5 $\pm$ 1,14*	19,6 $\pm$ 1,11*	15,6 $\pm$ 0,9*	14,1 $\pm$ 0,1*	12,5 $\pm$ 1,1*	10,2 $\pm$ 0,5*



INF-γ	0,9±1,1 *	2,6±1,1*	1,1±1,3 *	8,1±1,1*	0,8±1,1*	0,3±0,9*
Note: * – p<0,05.						

In addition, it has receptors that react with monocytes and neutrophils, which have the ability to cause a specific appearance, and stops these cells in the capillaries located in the area of inflammation. Such a high level of IL-8 indicates that the inflammatory process in the leg becomes chronic in a positive way. The dynamics of cytokine levels are more clearly shown in Figure 2. At the same time, changes in the level of IL-1β, IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ cytokines were noted, but within normal limits. Locally, in 2 cases, variants of purulent-necrotic injuries, which included not only two anatomical areas of the leg, but also with the spread of the process to the border of the upper and middle third of the leg, and in 3 cases - ended with gangrene of the distal parts of the leg. Cytokine regulation of the inflammatory reaction is insufficiently activated in patients with chronic DFS and secondary immunodeficiency with recurrence of the purulent-necrotic process. This leads to a lack of growth factors and slow healing. Perhaps this condition can be considered as a weak proliferative response. Accordingly, as a local process, the functional status of functional mononuclear phagocytes, platelets, macrophages, fibroblasts, keratocytes, endothelial

cells and other cells slows down with slow resorption of the infiltrate and the formation of necrosis.

Materials and methods of the third stage – main group. Taking into account the information obtained about the state of the cytokine system in patients with purulent-necrotic processes of DFS, it was decided to study the antioxidant effect of ozone therapy and the drug Reomannisol. The research group consists of 40 patients. With the neuropathic form of DFS - 16 people: 4 men and 12 women, and the neuroischemic form of DFS - 24 patients: 8 men and 16 women, aged 50 to 75 years. In the anamnesis, there were multiple recurrences of purulent-necrotic complications (from 2 to 4 times). The duration of diabetes is from 5 to 20 years. The goal of surgery and conservative treatment algorithm is to preserve the function of the leg or reduce the level of amputation. Reomannisol was used from the first day of hospitalization to study the antioxidant and peripheral blood circulation effects of the drug in complex treatment. According to the scheme, 200.0 ml of solution was administered intravenously 1 time per day for 10 days. Plasma sampling and cytokine levels were performed on the first day before and/or after surgery, and then on days

3, 5, 7, 10, and 12 again blood plasma was taken and the level of cytokines was determined.

Results and discussions in the third group. Table 6 lists the procedures performed in patients of group III.

Table 6. Characteristics of operations in group III		
Type of operation	Frequency of operations (n=35)	
	abs.	%
Amputations at the hip level	10	28,6
Amputations at the lower leg level	1	2,9
Amputations at the foot level	1	2,9
Amputations at the level of the fingers	15	42,8
Amputations at the level of the fingers	11	31,3
Necrectomy	15	42,9

Operations performed to save the leg: necroctomies - 42.9%, sequestrectomy - up to 31.3%, amputations at the level of toes - 42.8%, amputations at the level of the heel - 34.3%. In addition, the number of high amputations: at the hip level - 28.6%, at the heel level - 2.9%. Compared to the second group, the number of upper amputations decreased from 65.7% to 28.6%. In addition, the antioxidant effect of Reomannisol, manifested in the induction of inflammatory and anti-inflammatory cytokines, was determined. Cytokine levels in patients of study group III are presented in Table 7.

Table 7. The amount of cytokines after ozonotherapy + reomannisol treatment in group III patients, pg/ml						
Cytokines/ Days	Day 1	Day 3	Day 5	Day 7	Day 10	Discharge (11- 12 days)
IL-1β	64,59±3, 3*	74,48 ±1,9*	95,27±2,2 *	71,48± 1,8*	31,49 ±1,9*	20±1,8*
IL-2	1,2±0,3*	1,7±0, 13*	1,1±0,2*	0,54± 0,15*	0,2±0, 11*	0
IL-4	41,56±2,3	43,96	39,29±4,1	30,7±3	32,9±	20,58±2,2*

	*	±3,1*	*1	,2*	3,5*	
IL-6	228,92±5,1*	138±3,2*	50,8±2,1*	42,6±3,1*	38±2,1*	8,5±1,1*
IL-8	181,14±4,1*	197,31±3,1*	245,47±5,9*	222,6±4,5*	109,6±5,1*	53±1,1*
IL-10	48,8±2,8*	25,81±1,6*	34,2±2,1*	40,2±3,2*	38,7±2,5*	21,2±1,3*
TFN-α	147,86±4,6*	150,6±5,3*	121,96±5,4*	91,58±4,3*	41,1±2,1*	21,87±1,1*
INF-γ	194±3,4*	205,9±6,5*	89±4,1*	47,8±2,1*	7,8±0,4*	5,39±0,3*
Note: * – p<0,05.						

IL-1β: high level of cytokine up to 64.59±3.3 pg/ml on the first postoperative day, increased to 95.27±2.2 pg/ml on the fifth day and decreased to 20 ± 1.8 pg/ml. IL-1b promotes the proliferation of monocytes, macrophages, neutrophils, endothelium, smooth muscle cells, fibroblasts, keratinocytes, T- and B-lymphocytes, along with other cytokines; increases the stimulation of receptors for IL-2; activates endothelial cells; induces an acute phasic response.

IL-2: increases to 1.2±0.3 pg/ml on the first postoperative day, to 1.7±0.13 pg/ml on the third day, and to 0 at discharge. After an increase in IL-2, the active implementation of the immune response and the activation of T cells show.

IL-4: fluctuations were noted within normal limits and an increase was observed in only one case, that is, 76 pg/ml in a patient with an allergic background, which increased due to the development of postoperative traumatic dermatitis on the limbs after surgery. . It is possible that reomannisol stimulates the production of this cytokine by mononuclear cells in the peripheral blood of allergic patients. However, as a result of antioxidant activity, there are fluctuations in the group of cytokines with pro-inflammatory effects, but only within normal limits.

IL-6: a high level of cytokine up to 228.92±5.1 pg/ml was recorded on the first postoperative day. Then it gradually returns to normal, and by the time of discharge from the hospital, it was back to normal. IL-

6 is produced by T-lymphocytes, monocytes, macrophages, fibroblasts. Hematopoiesis causes the differentiation of progenitor cells, stimulates the development and production of megakaryocytes, promotes the growth and differentiation of platelets, T- and B-lymphocytes, and stimulates the production.

IL-8: peak cytokine levels increased to  $181.14 \pm 4.1$  pg/ml on the first postoperative day,  $245.47 \pm 5.9$  pg/ml on the fifth day, and  $53 \pm 1.1$  pg/ml at hospital discharge. decreased to ml. As revealed in the study of the previous two groups, the growth of this cytokine characterizes the transition of the process to a chronic form.

IL-10: An anti-inflammatory cytokine produced by T-lymphocytes, macrophages, keratinocytes, and B-lymphocytes. It blocks the functional activity of macrophages, the production of anti-inflammatory cytokines by monocytes and macrophages. It increases the proliferation of B-lymphocytes and the secretion of immunoglobulins IgE. However, IL-10 can stimulate the synthesis of IL-4 in a balanced state. By preventing the systemic response to the inflammatory process, IL-10 ensures a balanced level of inflammatory and anti-inflammatory cytokines, controls the immune response, which has a positive effect on the prevention of purulent-necrotic recurrence.

TNF- $\alpha$ : produced by macrophages, monocytes, keratinocytes, T-lymphocytes, B-lymphocytes,

neutrophils, endothelial cells. TNF- $\alpha$  has a variety of effects, occurs due to the modulation of the expression of genes for cell growth factors, cytokines, transcription factors, cell surface receptors and acute phase proteins, and plays an important role in protection against them. The increase of this cytokine on the third day up to  $150.6 \pm 5.3$  pg/ml after the operation is included in the high activity and the cytokine itself.

INF- $\gamma$ : on the first day, a high level was recorded to  $194 \pm 3.4$  pg/ml, on the third day it increased to  $205.9 \pm 6.5$  pg/ml and decreased to  $5.39 \pm 0.3$  pg/ml, this indicates its immunomodulatory value and involvement in the regulation of the anti-inflammatory response.

#### CONCLUSION

In the case of purulent-necrotic processes in DFS, the adequate introduction of the cytokine system is characterized by the slowing down of the local process, corresponding to acute inflammation, but increases the tendency of the process to go into a chronic state. With the recurrence of purulent-necrotic inflammation, there is a chronization of the process and a secondary immune deficiency, which does not allow the cytokine system to adequately join the anti-inflammatory system. Reomannisol allows us to consider it a physiologically active compound with clear antioxidant activity. Reomannisol has an



antioxidant effect on the cytokine system, correcting the cytokine balance. It can decrease the function of pro-inflammatory and anti-inflammatory cytokines, interferons. Reomannisol is effective in preventing recurrence of purulent-necrotic lesions of DFS in conditions of secondary immunodeficiency, so it is a necessary drug in the main therapy complex.

## REFERENCES

1. Yusufjanovich E. U. et al. Assessment of the Process of Epithelialization After Complex Treatment of Diabetic Foot Syndrome //Texas Journal of Medical Science. – 2023. – T. 16. – C. 19-23.
2. Зохиоров А. Р., Абдусаломов Б. А., Моминов А. Т. Совершенствование комплексного лечения с учетом патофизиологических изменений гнойно-некротических поражений нижних конечностей при сахарном диабете. – 2022.
3. Yusufjanovich E. U. et al. Treatment of purulent-necrotic lesions of the lower extremities with modern drugs //Conferencea. – 2023. – C. 88-94.
4. Ergashev U. Y. et al. THE STUDY OF DIAGNOSTICS AND PREVENTION OF PATHOPHYSIOLOGICAL PARAMETERS AFTER MODERN TREATMENT OF PURULENT-NECROTIC PROCESSES IN DIABETIC. – 2022.
5. Ergashev U. Y. et al. THE STUDY OF PATHOMORPHOLOGICAL DIAGNOSIS OF VITAL ORGANS AFTER MODERN TREATMENT OF DIABETIC FOOT SYNDROME. – 2022.
6. Rafiqovich Z. A. CONTROL OF INDICATORS OF ENDOTOXICOSIS IN DIABETIC FOOT SYNDROME //Conferencea. – 2023. – C. 83-90.
7. Rafiqovich Z. A. STUDY OF THE EFFECT OF LIPID PEROXIDASE ANALYSIS ON THE BODY IN DIABETIC FOOT SYNDROME //Conferencea. – 2023. – C. 76-82.
8. Rafiqovich Z. A. MONITORING OF THE REGENERATION PROCESS IN PURULENT-NECROTIC PROCESSES OF THE LOWER EXTREMITIES //Conferencea. – 2023. – C. 189-194.
9. Зохиоров А. Р. ОБОСНОВАНИЕ ПРОЦЕССОВ ЭПИТЕЛИЗАЦИИ И РЕГЕНЕРАЦИИ ПРИ ГНОЙНО-НЕКРОТИЧЕСКИХ ПРОЦЕССАХ НИЖНИХ КОНЕЧНОСТЕЙ ПРИ САХАРНОМ ДИАБЕТЕ //Conferencea. – 2023. – C. 174-180.
10. Ergashev U. Y. Ernazarov Kh. I., Zohirov AR, Alzabni ID 2022. Complex Treatment of Experimental Model of Diabetic Foot Syndrome //American Journal of Medicine and Medical Sciences. – 2022. – T. 12. – №. 5. – C. 471-480.
11. Rafiqovich Z. A. OBSERVATION OF BIOCHEMICAL RESULTS IN EXPERIMENTAL DIABETIC FOOT SYNDROME //Conferencea. – 2023. – C. 181-188.
12. Ergashev U. Y., Zokhirov A. R., Minavarkhujaev R. R. Determination of changes in the lipid peroxidase index in purulent-necrotic lesions of the lower extremities. – 2022.



13. Эрназаров Х. и др. ПАТОМОРФОЛОГИЧЕСКАЯ КАРТИНА ЖИЗНЕННО ВАЖНЫХ ОРГАНОВ ПРИ ЭКСПЕРИМЕНТАЛЬНОЙ МОДЕЛИ ДИАБЕТИЧЕСКОЙ СТОПЫ. – 2022.
14. Ergashev U. Y. et al. IMPROVING METHODS FOR DIAGNOSING AND MONITORING ENDOTOXICOSIS IN EXPERIMENTAL DIAETIC FOOT SYNDROME //World Bulletin of Public Health. – 2023. – Т. 19. – С. 84-95.
15. Эргашев У. Ю. и др. ИЗУЧЕНИЕ ПАТОМОРФОЛОГИИ ПЕЧЕНИ ПРИ ЭКСПЕРИМЕНТАЛЬНОМ СИНДРОМЕ ДИАБЕТИЧЕСКОЙ СТОПЫ //European Journal of Interdisciplinary Research and Development. – 2023. – Т. 12. – С. 27-31.
16. Зохиров А. Р., Набиева А. Ш. ИЗУЧЕНИЕ ПАТОМОРФОЛОГИЧЕСКИХ ОСОБЕННОСТЕЙ СОВРЕМЕННОГО ЛЕЧЕНИЯ ГНОЙНО-НЕКРОТИЧЕСКИХ ПРОЦЕССОВ ПРИ САХАРНОМ ДИАБЕТЕ //Interpretation and researches. – 2023. – Т. 1. – №. 2. – С. 25-36.
17. Эрназаров Х. И. и др. ЭФФЕКТИВНОСТЬ ИСПОЛЬЗОВАНИЕ ПРЕПАРАТА РЕОМАННИСОЛ В ЛЕЧЕНИИ ЭКСПЕРИМЕНТАЛЬНОЙ МОДЕЛИ ДИАБЕТИЧЕСКОЙ СТОПЫ. – 2022.
18. Зохиров А. Р., Эрназаров Х. И., Эргашев У. Ю. ПАТОМОРФОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ЗАЖИВЛЕНИЯ РАН ПРИ ЭКСПЕРИМЕНТАЛЬНОЙ МОДЕЛИ ДИАБЕТИЧЕСКОЙ СТОПЫ. – 64-ОЙ НАУЧНО-ПРАКТИЧЕСКОЙ КОНФЕРЕНЦИИ ОБУЧАЮЩИХСЯ «НАУКА И ЗДОРОВЬЕ» ПОСВЯЩЕННАЯ ДНЮ НАУКИ РЕСПУБЛИКИ КАЗАХСТАН С МЕЖДУНАРОДНЫМ УЧАСТИЕМ, 2022.
19. Yusufjanovich E. U. et al. PRINCIPLES OF STUDYING LIVER MORPHOLOGY IN EXPERIMENTAL DIABETIC FOOT SYNDROME //World Bulletin of Public Health. – 2023. – Т. 19. – С. 63-65.
20. Rafiqovich Z. A. et al. IMPROVING THE DETECTION OF MORPHOLOGICAL CHANGES IN PURULENT WOUNDS //E Conference Zone. – 2023. – С. 51-57.